FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

Dr Lipson discusses the significance of the regulatory decision for relatlimab and nivolumab, updated data from the RELATIVITY-047 trial, adverse effects clinicians should be aware of when prescribing the doublet, and the potential next steps for this therapy in melanoma.